Lipitor's Primary Mechanism
Lipitor (atorvastatin) inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. This blocks the conversion of HMG-CoA to mevalonate, reducing downstream cholesterol production in the liver.[1]
Does Lipitor Affect Protein Synthesis?
Lipitor does not directly target protein synthesis pathways like ribosomes, tRNA, or mRNA translation. Its main action is on lipid metabolism, not translation machinery.[1][2]
Indirect Effects on Protein Production
By depleting mevalonate, Lipitor reduces levels of isoprenoids (e.g., farnesyl and geranylgeranyl pyrophosphate). These lipids prenylate small GTPases like Rho, Ras, and Rac, anchoring them to membranes for activation.
- Prenylation inhibition disrupts GTPase function, indirectly downregulating genes and proteins involved in inflammation (e.g., NF-κB pathway), cell proliferation, and smooth muscle migration.[3]
- In cell studies, this leads to decreased synthesis of specific proteins like cyclin D1 or proinflammatory cytokines, but not broad protein synthesis.[4]
No evidence shows global inhibition of protein synthesis akin to cycloheximide or puromycin.
Clinical Relevance and Patient Concerns
These off-target effects contribute to Lipitor's benefits in atherosclerosis (reduced vascular inflammation) but raise risks like myopathy. Statin-induced myalgia may involve impaired prenylation of muscle proteins, though protein synthesis rates remain largely unaffected in vivo.[5]
Comparisons with Other Statins
All statins (e.g., simvastatin, rosuvastatin) share this mevalonate pathway inhibition. Lipitor's potency stems from its lipophilicity, enhancing cellular uptake and prenylation effects compared to hydrophilic pravastatin.[2]
[1] DrugPatentWatch.com - Atorvastatin Patents
[2] PubMed - Statin Mechanisms
[3] Nature Reviews - Pleiotropic Effects of Statins
[4] Journal of Biological Chemistry - Rho GTPase Inhibition
[5] NEJM - Statin Myopathy